Yield10 Bioscience, Inc. (YTEN)

Yield10 Bioscience, Inc. (YTEN) Materials & Commodity Exposure

Yield10 Bioscience, Inc. is an agricultural biotechnology firm developing advanced solutions to enhance crop productivity in the US and Canada. Leveraging its proprietary Trait Factory, the company creates improved oilseed Camelina sativa varieties and identifies valuable genetic traits for agriculture and food sectors, supported by licensing agreements with industry leaders.

What Is the Investment Thesis for YTEN?

Yield10 Bioscience, Inc. presents an investment profile centered on its innovative agricultural biotechnology platform and the potential commercialization of its proprietary crop traits. A key value driver is the company's Trait Factory, a gene discovery platform enabling the development of enhanced oilseed Camelina sativa varieties and other valuable genetic characteristics for agriculture and food. The ongoing research collaborations and licensing agreements with industry leaders like GDM Seeds and Bayer AG validate the potential of its technology and provide avenues for market penetration. Specific growth catalysts include the progress of field trials for novel traits, regulatory approvals for new crop varieties, and the expansion of its licensing portfolio. However, investors must consider the significant financial risks, evidenced by a profit margin of -24091.7% and a gross margin of -383.3%, reflecting the capital-intensive nature of biotech R&D. The company operates with a beta of 1.43, indicating higher volatility compared to the broader market. The time-intensive nature of bringing new traits to market and navigating complex regulatory hurdles are ongoing risks that necessitate close monitoring of development milestones and commercialization timelines.

Based on FMP financials and quantitative analysis

YTEN Key Highlights

• Market Capitalization of 345K, reflecting its early-stage commercialization and high-growth potential within agricultural biotechnology.
• Profit Margin of -24091.7%, indicating substantial investment in research and development and pre-commercialization operational costs.
• Gross Margin of -383.3%, highlighting the current stage of revenue generation relative to the cost of goods sold, typical for a biotech firm prior to widespread commercialization.
• Beta of 1.43, suggesting higher volatility compared to the overall market, consistent with a company in a high-growth, innovation-driven sector.
• A lean operational structure with 29 employees, focusing resources on specialized R&D and strategic partnerships.

Who Are YTEN's Competitors?

YTEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are YTEN's Key Strengths?

• Proprietary Trait Factory gene discovery platform for novel trait development.
• Focus on oilseed Camelina sativa, a versatile crop with multiple market applications.
• Existing licensing agreements with major agricultural industry players.
• Specialized expertise in agricultural biotechnology to enhance crop productivity.

What Are YTEN's Weaknesses?

• Significant negative profit and gross margins, indicating pre-profitability stage.
• Relatively small employee base (29 employees) for extensive R&D efforts.
• Dependence on successful field trials and regulatory approvals for commercialization.
• High capital requirements inherent in agricultural biotechnology research and development.

What Could Drive YTEN Stock Higher?

• Progress in field trials for enhanced oilseed Camelina sativa varieties, demonstrating improved yield and oil content under various environmental conditions.
• Achievement of key regulatory approvals for novel genetic traits in Camelina or other target crops, paving the way for commercialization in the US and Canada.
• Announcement of new or expanded licensing agreements with major agricultural or food industry partners, accelerating market penetration and revenue potential.
• Successful scale-up of Camelina seed production and processing capabilities to meet anticipated market demand for biofuel feedstocks and other applications.
• Publication of research data demonstrating the efficacy and sustainability benefits of Yield10's proprietary traits in target crops like canola, soybean, or corn.

What Are the Key Risks for YTEN?

• Significant negative profit margin (-24091.7%) and gross margin (-383.3%), indicating the company's current pre-profitability stage and high R&D investment.
• Protracted regulatory approval processes for novel genetically modified crops and traits, which can delay commercialization timelines and increase development costs.
• The time-intensive nature of agricultural biotechnology research and development, requiring sustained capital investment without immediate returns.
• Intense competition from larger, well-capitalized agricultural science companies with established market presence and extensive R&D budgets.
• Market acceptance challenges for new crop varieties or traits among farmers, processors, and consumers, impacting adoption rates and revenue generation.

What Are the Growth Opportunities for YTEN?

• **Commercialization of Oilseed Camelina Sativa**: Yield10 Bioscience is focused on developing Camelina sativa as a versatile oilseed crop. This presents a significant growth opportunity as Camelina can serve multiple markets, including renewable diesel, sustainable aviation fuel (SAF), animal feed, and potentially human nutrition. The global demand for sustainable oils and biofuels is rapidly expanding, driven by environmental regulations and consumer preferences. By establishing Camelina as a low-carbon intensity feedstock, Yield10 can tap into a multi-billion dollar market, with timelines dependent on regulatory approvals and market adoption. Its proprietary traits aim to enhance yield and oil content, providing a competitive edge in this emerging market.
• **Expansion of Trait Factory Applications**: The proprietary Trait Factory gene discovery platform is a core asset, enabling the identification and development of valuable genetic characteristics beyond Camelina. This platform can be applied to major row crops such as canola, soybean, and corn, as indicated by the company's focus on enhancing oil production and seed yield in these crops. Expanding the application of its yield-enhancing traits to these large-acreage crops represents a substantial market opportunity. The ability to license these traits to major seed companies could generate significant royalty revenues, with timelines linked to successful field trials and regulatory approvals for each new trait and crop combination.
• **Strategic Licensing and Partnership Expansion**: Yield10 Bioscience currently holds licensing agreements with key industry players like GDM Seeds, J. R. Simplot, Forage Genetics International, LLC, and Bayer AG. Expanding these strategic partnerships and forging new ones is a critical growth driver. These collaborations provide access to broader distribution networks, accelerate market penetration, and validate the efficacy of Yield10's technologies. New agreements could target specific geographic regions or crop segments, leveraging partners' market expertise and resources to bring novel traits to farmers more efficiently. The success of these partnerships directly impacts the speed and scale of commercialization.
• **Development for Biofuel Feedstock Markets**: The increasing global emphasis on decarbonization and the transition to renewable energy sources creates a robust market for biofuel feedstocks. Yield10's focus on oilseed Camelina sativa positions it to become a significant player in supplying feedstock for renewable diesel and sustainable aviation fuel (SAF). The market for these fuels is projected to grow substantially over the next decade, driven by government mandates and corporate sustainability goals. By optimizing Camelina for high oil yield and favorable fatty acid profiles, Yield10 can capture a share of this high-value market, offering a sustainable and domestically sourced alternative to traditional feedstocks.
• **Entry into Food and Feed Ingredient Markets**: Beyond industrial applications, the enhanced Camelina sativa developed by Yield10 Bioscience holds potential for the food and animal feed industries. Camelina oil is naturally rich in omega-3 fatty acids, making it a candidate for healthy cooking oils, nutritional supplements, and functional food ingredients. In animal feed, Camelina meal can provide a protein-rich supplement. Tapping into these markets would diversify Yield10's revenue streams and leverage consumer demand for healthier, sustainably produced ingredients. Market entry would involve demonstrating nutritional benefits and securing regulatory approvals for food and feed applications, with a long-term growth trajectory.

What Opportunities Does YTEN Have?

• Expanding applications of Camelina sativa into biofuel, food, and animal feed markets.
• Leveraging the Trait Factory to develop traits for other major crops like canola, soybean, and corn.
• Forging new strategic partnerships and licensing agreements to broaden market reach.
• Increasing global demand for sustainable agriculture and alternative protein/oil sources.

What Threats Does YTEN Face?

• Intense competition from larger, well-established agricultural science companies.
• Stringent and time-consuming regulatory hurdles for novel genetically modified crops.
• Market acceptance risks for new crop varieties and traits among farmers and consumers.
• Potential for intellectual property infringement or challenges to patent protection.

What Are YTEN's Competitive Advantages?

• Proprietary 'Trait Factory' gene discovery platform, enabling unique trait development.
• Exclusive seed products, particularly enhanced oilseed Camelina sativa varieties.
• Existing licensing agreements with established industry players, providing market access and validation.
• Specialized expertise in agricultural biotechnology and crop genetics.

What Does YTEN Do?

Yield10 Bioscience, Inc. is an agricultural biotechnology firm established in 1992, initially incorporated as Metabolix, Inc. before rebranding in January 2017. Headquartered in Woburn, Massachusetts, the company is dedicated to creating advanced solutions designed to significantly boost crop productivity across the United States and Canada. At the core of its operations is the proprietary Trait Factory, an innovative gene discovery platform. This platform is utilized to develop enhanced varieties of oilseed Camelina sativa, which are then commercialized as exclusive seed products. Beyond Camelina, the Trait Factory also serves to identify valuable genetic characteristics that have broad applicability across both the agricultural and food sectors, aiming to improve traits such as oil production and seed yield in various crops. Yield10 Bioscience maintains strategic licensing agreements with several key industry players, including GDM Seeds, J. R. Simplot, Forage Genetics International, LLC, and Bayer AG. These collaborations are crucial for the development, testing, and potential market adoption of its novel traits and crop varieties. The company's focus on developing novel traits in crops like canola, soybean, and corn, alongside its primary work with Camelina, positions it within the specialized niche of agricultural innovation, striving to address global demands for increased and more sustainable food, feed, and industrial oil production.

What Products and Services Does YTEN Offer?

• Develops advanced agricultural biotechnology solutions to enhance crop productivity.
• Utilizes a proprietary 'Trait Factory' platform for gene discovery and trait development.
• Creates enhanced varieties of oilseed Camelina sativa for exclusive seed products.
• Identifies valuable genetic characteristics applicable to both agricultural and food sectors.
• Focuses on improving traits like oil production and seed yield in crops.
• Maintains licensing agreements with major industry players like GDM Seeds, J. R. Simplot, and Bayer AG.
• Aims to boost crop yields across the United States and Canada.

How Does YTEN Make Money?

• Develops proprietary genetic traits and enhanced crop varieties through its Trait Factory platform.
• Generates revenue through licensing agreements with agricultural companies for the use of its traits and seeds.
• Commercializes exclusive seed products, particularly enhanced oilseed Camelina sativa.
• Conducts research and development to identify new genetic characteristics for various crops.

What Industry Does YTEN Operate In?

Yield10 Bioscience operates within the Agricultural Inputs industry, a critical segment of the Basic Materials sector focused on providing essential resources for crop production. This industry is characterized by a growing global demand for food, feed, and renewable resources, driving innovation in crop yield enhancement and sustainable agriculture. Market trends include increasing adoption of biotechnology to improve crop resilience, nutritional content, and resource efficiency, alongside a push for alternative oilseed crops for biofuels and healthier food products. Yield10 Bioscience positions itself as a developer of proprietary genetic traits and enhanced oilseed Camelina sativa, differentiating itself through its Trait Factory platform. The competitive landscape includes large agricultural science companies and specialized biotech firms. Yield10's strategy of developing novel traits and leveraging licensing agreements aims to carve out a niche by offering advanced solutions that can be integrated into existing agricultural supply chains, addressing the industry's need for increased productivity and sustainability.

Who Are YTEN's Key Customers?

• Large agricultural seed companies and biotechnology firms seeking advanced crop traits.
• Farmers in the United States and Canada who purchase enhanced Camelina sativa seeds.
• Companies in the food and feed sectors interested in novel ingredients derived from crops.
• Biofuel producers seeking sustainable, high-yield oilseed feedstocks.

Company Profile

Yield10 Bioscience, Inc. operates in the Agricultural Inputs industry within the Basic Materials sector. It is headquartered in Woburn, US. The company is led by CEO Oliver P. Peoples. YTEN has traded publicly since 2006.

FY2026 estForward Outlook

Wall Street analysts project Yield10 Bioscience, Inc. revenue of about $26.8M for fiscal 2026, with EPS near $-3.36.

F-Score 4/9Financial Health

Yield10 Bioscience, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

YTEN Valuation & Market Position

With a 345K market cap, Yield10 Bioscience, Inc. sits in the micro-cap segment of the market. Relative to its peer group, YTEN's quantitative score of 43/100 is below the peer average of 67/100.

YTEN Financials

YTEN Latest News

No recent news available for YTEN.

YTEN Analyst Consensus

YTEN MoonshotScore

Common Questions About YTEN (Basic Materials)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources